The Carlucci lab research interests are aimed to develop novel radiopharmaceuticals for targeted diagnosis and treatment of cancer. Their strategy is to combine small targeting biomolecules with positron-emitting or therapeutic radioisotopes. They characterize molecular profiles of cancer using noninvasive nuclear imaging, identify metabolic and immunology key targets and treat tumors specifically with targeted radiotherapy. Our ultimate goal is to clinically unravel the potential of molecular imaging and combine it with the therapy potential of nonstandard nuclides.
Carney, Brandon; Carlucci, Giuseppe; Salinas, Beatriz; Di Gialleonardo, Valentina; Kossatz, Susanne; Vansteene, Axel; Longo, Valerie A; Bolaender, Alexander; Chiosis, Gabriela; Keshari, Kayvan R. Noninvasive PET imaging of PARP1 expression in glioblastoma models. Molecular imaging and biology. 2016; 18(3): 386-392
Carlucci, Giuseppe; Carney, Brandon; Sadique, Ahmad; Vansteene, Axel; Tang, Jun; Reiner, Thomas. Evaluation of [18F]-ATRi as PET tracer for in vivo imaging of ATR in mouse models of brain cancer. Nuclear medicine and biology. 2017; 48: 9-15.
Jannetti, Stephen A; Carlucci, Giuseppe; Carney, Brandon; Kossatz, Susanne; Shenker, Larissa; Carter, Lukas M; Salinas, Beatriz; Brand, Christian; Sadique, Ahmad; Donabedian, Patrick L. PARP-1–Targeted Radiotherapy in Mouse Models of Glioblastoma. Journal of Nuclear Medicine. 2018; 1225-1233.
Ramos, Nicholas; Baquero-Buitrago, Jairo; Gironda, Zakia Ben Youss; Wadghiri, Youssef Zaim; Reiner, Thomas; Boada, Fernando E; Carlucci, Giuseppe. Noninvasive PET Imaging of CDK4/6 Activation in Breast Cancer. Journal of Nuclear Medicine. 2020; 437-442.
Carlucci, Giuseppe; Ippisch, Robin; Slavik, Roger; Mishoe, Ashley; Blecha, Joseph; Zhu, Shaojun. 68Ga-PSMA-11 NDA approval: a novel and successful academic partnership. Journal of Nuclear Medicine. 2021; 149-155.